Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks seen muted as oil prices rise
(Sharecast News) - London stocks were set for a muted open on Tuesday ahead of a slew of UK data releases, as investors digested news that EU leaders have agreed to ban 90% of Russian oil by the end of the year. The FTSE 100 was called to open unchanged at 7,600.
CMC Markets analyst Michael Hewson said: "Asia markets have undergone a mixed session, in the aftermath of these numbers, and while things may be improving in the Chinese economy, the continued rise in oil prices is likely to act as a drag on economic activity, after EU leaders agreed a deal to block 90% of oil imports by the end of this year.
"As a result of this drag, European markets look set to open cautiously lower."
On the UK macro front, net lending, consumer credit and mortgage approvals for April are due out at 0930 BST.
In corporate news, B&M European Value Retail said UK like-for-like sales over the first eight weeks of the current financial year were down 13.2% and 11.5% against 2022 and 2021 respectively amid inflationary pressures and the cost-of-living crisis.
It also announced flat annual profits for the year to March 26 and said chief financial officer Alex Russo would be replacing Simon Arora as CEO.
Drugmaker GlaxoSmithKline said it had agreed to acquire Boston-based clinical-stage biopharmaceutical company Affinivax as part of a deal valued at as much as $3.3bn.
GlaxoSmithKline will make an upfront payment of $2.1bn for Affinivax, with another $1.2bn in potential development milestones to follow upon the achievement of certain paediatric clinical development milestones. Under the terms of the agreement, GSK will acquire 100% of the outstanding shares of Affinivax.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.